|Summary sheet: 4-FMA|
|Psychoactive class||Stimulant / Entactogen|
|Routes of Administration|
|Psilocybin mushrooms|Psilocybin mushrooms|
4-Fluoromethamphetamine (also known as 4-FMA) is a lesser-known novel stimulant-entactogen substance of the amphetamine class. 4-FMA is chemically related to 4-FA and methamphetamine. Little is known about its pharmacology, but it likely produces its effects by increasing levels of dopamine, norepinephrine, and serotonin in the brain.
4-FMA was first detected being sold in Japan as a legal high in 2006. It has been sold online as a research chemical alongside 2-fluoroamphetamine (2-FA), 3-fluoroamphetamine (3-FA) and 4-fluoroamphetamine (4-FA).
User reports describe the effects of 4-FMA as having characteristics of both traditional stimulants like amphetamine and entactogens like MDMA. Its effects have been described as subjectively lying between 4-FA and 2-FMA. It has been reported to be more likely to produce side effects like headaches and cardiovascular effects than similar substances.
Very little is known about the pharmacological properties, metabolism, and toxicity of 4-FMA. 4-FMA use may produce dependence and abuse as well as damage to the brain and other organs. It is highly advised to use harm reduction practices if using this substance.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
4-Fluoromethamphetamine (4-FMA) is a synthetic molecule of the substituted amphetamine family. Molecules of this class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. The term "amphetamine" is the contracted form of alpha-methylphenethylamine. 4-fluoromethamphetamine contains a fluorine atom at R4 of its phenyl ring and is therefore a fluorinated analogue of methamphetamine.
Similar to its structural analog 4-FA, 4-Fluoromethamphetamine is thought to act as a releasing agent and reuptake inhibitor of dopamine, serotonin, and norepinephrine, producing stimulating amphetamine-like effects at lower doses and more euphoric, entactogen effects similar to MDA at dosages above 125mg. [avoid opinion] Researchers have found some evidence that indicates some similarities between the "Serotonin Release" of 4-FMA and other popular empathogens such as: MDA, 4-Methylmethcathinone, and 4-fluoroamphetamine. .
The mechanism of action of 4-FMA effectively boosts the levels of the norepinephrine, dopamine, and serotonin neurotransmitters in higher doses in the brain by binding to and partially blocking the transporter proteins that normally clear these monoamines from the synaptic cleft. This allows dopamine, norepinephrine, and serotonin to accumulate within various regions of the brain, including its reward pathways, resulting in stimulating, euphoric and entactogenic effects..
In low doses, 4-FMA has been reported to be a lackluster nootropic for general productivity. Such usage would be strongly discouraged however, due to the increased risks for neurotoxicity and other dangerous side-effects. The reasoning for this warning is based on the studies showing that 4-FMA is similar to MDA, and belongs to the entactogen class. Using any entactogen frequently is considered dangerous, and it is seen as unwise to take "microdoses" below the minimum dose required to experience a "roll" with members of the entactogen class. At higher dosages, it is known to become dysfunctional and recreational due to the scattering quality of its euphoria and stimulation.
Similar to MDA, MDMA, 4-FA, and other substances that produce distinct pleasurable tactile "roll"-like sensations, which is typically linked to serotonin-releasing properties, 4-FMA has been reported to be able to produce similar entactogenic effects in addition to traditional stimulant ones. Some reports suggest it tends to come with more side effects and bodily strain than other fluorinated amphetamines, explaining its lack of popularity and availability.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Stimulation - The stimulation which 4-FMA presents can be described as being a mix between a typical entactogen stimulation and the stimulation style of Methamphetamine.
- Tactile enhancement - This component, relative to other fluorinated amphetamines like 2-FA or 3-FA, has been reported to be a distinct aspect of the experience.
- Physical euphoria - This effect is extremely intense when compared to its physical stimulation.
- Bodily control enhancement
- Stamina enhancement
- Pupil dilation
- Appetite suppression
- Orgasm suppression
- Dehydration
- Increased perspiration
- Increased bodily temperature
- Increased heart rate
- Temporary erectile dysfunction
- Teeth grinding
- Vibrating vision
- Restless leg syndrome
- Muscle contractions
- Dizziness
- Abnormal heartbeat
- Euphoria - This effect has been reported to occur a series of euphoric waves that recede and reappear randomly throughout the experience. It is distinctly present at dosages above 100mg.
- Empathy, affection, and sociability enhancement - Varying reports differ on the level of this effect, with some reports comparing 4-FA and others comparing MDMA.
- Immersion enhancement
- Novelty enhancement
- Increased music appreciation
- Motivation enhancement'
- Delusion - As with most potent stimulants, 4-FMA has been reported as having the capacity to produce delusional ideation. However, it is not clear if this occurs in a context unique to the effects of 4-FMA.
- Ego inflation - Some users have reported that this component is distinct, although it is not clear how it compares to other substituted and non-substituted amphetamines.
- Stamina enhancement
- Thought acceleration
- Focus enhancement
- Analysis enhancement
- Increased libido
- Time distortion - This can be described as the experience of time speeding up and passing much quicker than it usually would when sober.
- Compulsive redosing
- Paranoia - As with most strong stimulants, 4-FMA has been reported to produce states of paranoia, although it is not clear to which extent this happens relative to other stimulants and under what conditions.
- The effects which occur during the offset of a stimulant experience generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a "comedown" and occurs because of neurotransmitter depletion. Its effects commonly include:
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
Do not use 4-FMA if you have a history of heart-related issues or experience severe headache after its use. We have been made aware of a report released by Trimbos-instituut and Nationaal Vergiftigingen Informatie Centrum (NVIC), describing incidents of strokes after an increased use of the closely related analogue 4-FA, and there is no reason this does not apply to 4-FMA as well. In addition to the common amphetamine-like effects (agitation, anxiety, tachycardia, hypertension, chest pain et al.), serious cardio- and cerebrovascular complications have been reported, including rhythm (sinus arrhythmia, ventricular extrasystoles (bigeminy), conduction disturbances) and acute cardiac failure. Although a causal relationship has not been confirmed, when presented with a severe headache and lateralization after 4-FA usage, a medical evaluation at an emergency department should be conducted immediately. 
The toxicity and long-term health effects of recreational 4-FMA use has not been studied in any scientific context and the exact toxic dosage is unknown. This is because 4-FMA has very little history of human usage. Anecdotal evidence suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).
The LD50 (mouse; i.p.) of 4-FMA is unknown. While 4-FA does not cause long-lasting depletion of brain serotonin unlike MDMA or 4-FA's analogs 4-CA and 4-BA, it is unknown whether this also applies to 4-FMA as well.
4-FMA is reported to be particularly caustic in comparison to other compounds and can, therefore, cause chemical burns within the nasal passage and throat if it is insufflated.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
As with other stimulants, the chronic use of 4-FMA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of 4-FMA develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). This is how long it takes to reduce the tolerance for the stimulating effects. Tolerance for the entactogenic effects may take a longer period to reduce. 4-FA presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of 4-FMA all stimulants will have a reduced effect.
Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions). A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely. The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis. Psychosis very rarely arises from therapeutic use.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when taken with other substances. The following lists some known dangerous combinations, but cannot be guaranteed to include all of them. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from Tripsit.
- Alcohol|Alcohol - Drinking on stimulants is considered risky because it reduces the sedative effects of the alcohol that the body uses to gauge drunkenness. This often leads to excessive drinking with greatly reduced inhibitions, increasing the risk of liver damage and increased dehydration. The effects of stimulants will also allow one to drink past a point where they might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less.
- Cannabis|Cannabis - Stimulants increase anxiety levels and the risk of thought loops and paranoia which can lead to negative experiences.
- GHB|GHB/GBL|GBL - Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the opiate may overcome the user and cause respiratory arrest.
- Opioids|Opioids - Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
- Cocaine|Cocaine - This combination of stimulants will increase strain on the heart. It is not favored as cocaine has a mild blocking effect on dopamine releasers like amphetamine.
- Caffeine|Caffeine - This combination of stimulants is generally considered unnecessary and may increase strain on the heart, as well as potentially causing anxiety and physical discomfort.
- Tramadol|Tramadol - Tramadol and stimulants both increase the risk of seizures.
- DXM|DXM - Both substances raise heart rate, in extreme cases, panic attacks caused by these substances have led to more serious heart issues.
- Ketamine|Ketamine - No unexpected interactions. Likely to increase blood pressure but not an issue with sensible doses. Moving around on high doses of this combination may be ill advised due to risk of physical injury.
- PCP|PCP - Increased risk of tachycardia, hypertension, and manic states.
- Methoxetamine|Methoxetamine - Increased risk of tachycardia, hypertension, and manic states.
- Psychedelics|Psychedelics (Psilocybin mushrooms|Psilocybin mushrooms, Mescaline|mescaline, LSD|LSD, DMT|DMT, 2C-x|2C-x, 2C-T-x|2C-T-x, 5-MeO-xxT|5-MeO-xxT, DOx|DOx) - The increased anxiety caused by stimulants is magnified by psychedelics and results in an increased risk of anxiety, paranoia, and thought loops.
- 25x-NBOMe|25x-NBOMe - Amphetamines and NBOMes both provide considerable stimulation that when combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
- MAOIs|MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with amphetamine can lead to hypertensive crises.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Canada: 4-FMA would be considered Schedule I as it is an analogue of Amphetamine.
- China: As of October 2015 4-FMA is a controlled substance in China.
- New Zealand: 4-FMA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.
- United Kingdom: 4-FMA is a Class A drug under the Misuse of Drugs Act. 4-FMA is covered by the 1977 addition to the Misuse of Drugs Act of 1971.
- Germany: 4-FMA is controlled under BtMG Anlage II, making it illegal to manufacture, import, possess, sell, or transfer it without a license.
- Machiko Nagashima; Takako Seto; Misako Takahashi; Jin Suzuki; Ichirou Yasuda (2006). "Spectrum Data of the 3rd Governor-designated Drugs and the Analyses of Uncontrolled Drugs Purchased" (PDF). Annu. Rep. Tokyo Metr. Inst. Public Health. 57: 109–113.
- The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17223101
- Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs). (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/15639609
- https://www.ncbi.nlm.nih.gov/pubmed/25624004 | Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones.
- http://www.sciencedirect.com/science/article/pii/0028390875900994 | Comparison of 4-chloro-, 4-bromo-and 4-fluoroamphetamine in rats: drug levels in brain and effects on brain serotonin metabolism
- http://www.sciencedirect.com/science/article/pii/S0014299906013811 | The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
- 4-fluoromethamphetamine (Reddit) | https://www.reddit.com/r/researchchemicals/comments/57fpu3/4fma_short_response/
- Treatment for amphetamine psychosis | 
- Treatment for amphetamine psychosis | 
- Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
- Treatment for amphetamine psychosis | 
- Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf
- Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
- "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.